Pfizer Ups Bid for Metsera in Obesity-Drug Showdown with Novo

What happened

Pfizer ($PFE) won a roughly $10B bidding war to acquire obesity drug developer Metsera ($MTSR) after Novo Nordisk ($NVO) stepped aside citing US antitrust risk. The deal gives Pfizer a fast track back into the GLP-1 weight loss market and could close after Metsera’s 13 Nov shareholder vote. Reuters notes Metsera’s pipeline (GLP-1 and amylin candidates) and long-run obesity market upside.

Why it matters

Pfizer previously halted its own GLP-1 pill program (danuglipron) and is buying its way back into the category. Consolidation and a bigger US player should ripple across obesity drug developers, CROs and life-science tools, and payers exposed to GLP-1 costs.

Winners -

Category: Big Pharma pivoting into obesit ...